Brandon Young

Brandon Young has 20 years of experience utilizing technology to improve testing and detection of genetic variation in human diseases. He was one of the early laboratory pioneers in microarray and gene sequencing projects in startup companies and large academic institutions. He has extensive experience in research, set-up, operations, configuration and P&L of running genomics labs. He has provided data and analysis for multiple national and international clinical trials.

Brandon has helped design, build and run labs for a number of prestigious centers throughout the US, including Scripps Florida, Human Longevity Institute (HLI), and Avera McKennan. His current work with the Darwin Foundation is providing next generation sequencing services to support groundbreaking clinical studies for the WIN consortium, focusing on personalized precision oncology testing and treatment protocols. This early stage work is generating over 50% improvements in clinical outcomes for participating cancer patients.

Deepankar Roy

Deepankar Roy is a trained research scientist and has worked on several cell line engineering platform technologies at Larix Bioscience and Genentech. Prior to these roles, he was a postdoctoral fellow at Genentech’s Research Oncology division where he studied cancer signaling pathways. Deepankar completed his doctoral studies in Biochemistry and Molecular Biology at University of Southern California where he undertook a reductionist approach in studying nucleic acid behavior in mammalian immune systems.

He has worked with early stage life science companies as Director of Business and Scientific Operations at Venomyx Inc., an antivenom therapeutics startup and as the Director of Business/Product Development at Colby Pharmaceutical Company and its subsidiary CancerVacs Inc, companies involved in development of immunotherapeutics for allergy, cancer and other diseases.

Jay Goth

Jay Goth is the Managing Partner of Forentis Fund, a biotech venture capital firm focused on precision medicine. He is a veteran entrepreneur, with experience in the hospitality, energy, finance and technology verticals. As a founding executive of Commonwealth Energy, Jay helped the company go from start-up to almost $500 million in revenues in five years, becoming the largest unregulated supplier of electricity and natural gas in the country when the company went public on the AMEX.

He serves as Executive Director of InSoCal CONNECT, a nonprofit that has structured mentorship and training programs for entrepreneurs, was a Senior Consultant with TriTech SBDC, one of seven technology designated Small Business Development Centers operating under the SBA, and served as an Entrepreneur in Residence at the University of California Riverside. Jay also serves on the board of directors for Credence Code Technologies, Inc., a company focused on blockchain development and implementation. He also serves on the board of Burble, a company that delivers the power of story through minimally defined immersive environments. Jay is on the board of directors for InSoCal CONNECT and Reach Out, nonprofits dedicated to improving lives in the Inland Empire.

John Powers

John Powers spent 22 years in the wireless industry driving acceptance and adoption of new technologies. His background in wireless convergence and high technology is complimentary to the goals of the medical industry, especially in integrating the large amount of genetic/genomic data into everyday medicine.

As CEO of IntraOp Medical, John worked with multiple discipline teams including physicists, surgeons, radiation and medical oncologists in the top cancer centers around the world. Working with the Centers for Medicare & Medicaid Services (CMS) John was able to secure a new reimbursement code and reimbursement for Intra-Operative Radiation Therapy (IORT). He more than tripled IntraOp’s installed customer base, making the company profitable in 2012, followed by a take private restructuring and change of ownership.

Advisory Board

We have assembled a dynamic and dedicated group of advisory board members to provide guidance to our incubator companies. Their crucial insights and experience will be invaluable to our startups. Most early stage companies would never have access to this type of knowledge base – one of the many benefits our clients enjoy.

Dr. Jay Harness, Chairman

Dr. Jay Harness is a surgeon specializing in complete breast health, breast cancer surgery, oncoplastic reconstruction, genetic screening, risk assessment and counseling, management of breast health issues and Breast Cancer Treatment in Orange County, California and is a global leader in the fight against breast cancer.

He most recently served as President of Breast Surgery International, and has served in leadership roles within a number of national and international professional associations including, most notably, as President of the American Society of Breast Surgeons from 2007 to 2008. Dr. Harness is the Chairman of Murrieta Genomics’ Advisory Board.

Anna Koelln

Anna brings a strong background in consulting and strategic planning within both the Healthcare industry and the public sector.

Since 2015 Anna has worked designing and implementing value based care initiatives, specifically focused on medical and surgical bundled payments for Medicare and Medicare Advantage. She is on multiple advisory boards of companies invested in emerging Healthcare-related technology fields. 

Most recently Anna was Vice President of Bundled Payments at United Healthcare, overseeing 22 markets nationwide, advising acute and post acute providers, hospitals and payers on operational and clinical strategies to streamline patient care, improve communications, and increase savings.

Anna managed a team of people at Remedy Partners, in both the California and Hawaii markets, focused on strategies for improving post-acute care. Utilizing analytic data, Anna guided hospital executives towards operational levers which exponentially improved performance outcomes in the post-acute space.

In addition, Anna has expertise in third party reproduction where she has consulted with intended parents and surrogates to help them understand the intersections of state legislation and policies, IVF clinic processes, health insurance coverage and care coordination with women’s health providers to successfully navigate the complexities of surrogacy.

Prior to working in Healthcare, Anna spent nearly a decade within the public sector working as the Wisconsin State Manager for the American Institutes for Research.  She worked directly with the Wisconsin Department of Public Instruction, Governor’s office, and Milwaukee Public Schools in leading project teams to develop and implement new policies and state-wide initiatives.

Anna excels at team building, developing long term partnerships, and identifying solutions for her clients by establishing trust and building consensus. Anna received her B.A. from Towson University and her M.A. from Johns Hopkins University.

Arie Shen

For more than two decades, Arie managed and led software projects, software creation and implementations and ran operations with sales responsibility for publicly traded software vendors.

Subsequently, he has enjoyed a diverse and successful consulting career growing companies and leveraging business opportunities. With his broad international background, experience and training, he has successfully guided a wide range of companies, including B2B, B2C and non-profit organizations. In addition to technology project management, Arie is expert in creating and implementing management strategy: developing and executing market penetration, defining strategies for growth and allocating resources to achieve them, and selecting and negotiating joint venture opportunities.

Software creation and implementation, Executive Sales and Business Development, Branding and Marketing, Technology Project Management, Entrepreneur and Investor.

Brian Leyland-Jones, M.B., B.S., Ph.D.

Dr. Leyland-Jones received biochemistry, medical and doctoral degrees from the University of London and completed his residency at Hammersmith, Brompton, St. Bartholomewís and London hospitals. He then conducted fellowships at Cornell University and Memorial Sloan-Kettering Cancer Center. He became part of Sloan-Kettering’s medical staff, researching new anti-cancer compounds.

From 1983-1990, Dr. Leyland-Jones served at the National Cancer Institute as head of Developmental Chemotherapy and he oversaw the development of approximately 70 anti-cancer compounds. From 1990-2000, he was the director of the McGill University Comprehensive Cancer Centre and the founding chair of Oncology. Dr. Leyland-Jones also served as a professor of medicine at McGill University. From 2007-2012, he was the Director of the Winship Cancer Institute at Emory University, as well as a Professor of Medicine and Associate Vice-President of Health Sciences.

Dr. Leyland-Jones has also worked in the private sector. He became Founding Chairman and Chief Executive Officer of Xanthus (a biotech company focused on individualized cancer therapies in 2001), and he has been the Director of Genta, Inc. since April 2012. Dr. Leyland-Jones is also a member of the Scientific and Clinical Advisory Boards at Welichem Biotech Inc. and Antigen Express Inc.

Currently, Dr. Leyland-Jones is the Vice President of Molecular and Experimental Research at the Avera Cancer Institute and the Director of the Darwin Foundation. Dr. Leyland-Jones has held leadership positions in many large medical organizations, including the Eastern Cooperative Oncology Group, the Tissue Bank Consortium in Asia (that was founded and operated by NFCR), the Cancer and Leukemia Group B, the International Breast Cancer Study Group, the National Cancer Institute of Canada and Breast International Group. He is also the Director of the Darwin Foundation (formerly the Consortium for Clinical Diagnostics) that provides a centralized infrastructure where disease genes and genetic signatures can be identified and validated.

He has received many awards and honors throughout his career, including the Vivian Saykaly Visiting Professor Award by the Cedars Cancer Institute in Montreal and being named an Eminent Scholar by the Georgia Research Alliance and a Distinguished Cancer Scholar by the Georgia Cancer Coalition.

Throughout his career, Dr. Leyland-Jones has written more than 180 peer-reviewed articles and book contributions, and he holds 34 patents.

David Cutler, MBA, CPA, CGMA, CVA

David J Cutler is principal at Cutler & Co., LLC, a Colorado based public accounting firm, that specializes in the providing outsourced chief financial officer and controller services to start up businesses and a veteran entrepreneur who has participated in multiple start up businesses.

Having qualified with Arthur Andersen and held senior financial management positions with a number of large multinational corporations, for the last 20 years David has specialized in providing auditing or chief financial officer services to start ups and small publicly quoted companies.

David has a Master’s degree from St. Catharine’s College in Cambridge, United Kingdom and qualified as a British Chartered Accountant and Chartered Tax Advisor with Arthur Andersen & Co. in London, United Kingdom. He was subsequently admitted as a Fellow of the UK Institute of Chartered Accountants. Since arriving in the US over 20 years ago, Mr. Cutler has qualified as a Certified Public Accountant, a Certified Valuation Analyst of the National Association of Certified Valuation Analysts and obtained an executive MBA from Colorado State University.

David offers a truly unique blend of proven leadership skills, elite level technical expertise, deep entrepreneurial experience, and a hands-on approach to financial problem solving.

Denise DeMan

With an indefatigable, pioneering and entrepreneurial spirit, DeeDee has taken Bench International from its founding in 1974 to its eminence today as one of the most successful companies ‘shattering’ diversity ceilings bringing women, people of color, as well as those who “think” and “do” differently to leadership roles in life science companies. In 2009 DeeDee was the first executive recruiter to be named “1 of the Top 100 Most Inspiring Leaders” by PharmaVOICE Magazine, and is a Hall of Fame Inductee of the National Association of Women Business Owners (NAWBO).

Being cause-motivated and giving back is critical to DeeDee, and she has devoted decades to serving as a member of multiple non-profit boards. She is a founding board member of Learning Forum International (LFI), Making Great Kids Greater through student and educator programs that contribute to the mastery of learning and life skills by today’s youth. Recently, DeeDee was appointed to the Advisory Board of BIOCOM, in an effort to bridge BIOCOM’S impact beyond San Diego County and to create a strong state-wide alliance. DeeDee is also a board member of The Maple Counseling Center (TMCC), a non-profit organization committed to providing low cost comprehensive mental health services for individuals of all ages, couples, and families, as well as providing training for interns and counselors who are working towards licensure in the mental health field.

DeeDee’s prior non-profit board commitments have included founding the Forum for Global Pharmaceutical Diversity and Inclusion (FRXDI), serving as a member of the board for California’s Chapter of the Israel International Cancer Research Fund (ICRF), Family Promise, and founding board member of Healthcare Business Woman’s Association’s (HBA’s) Europe Chapter.

DeeDee holds a double Masters of Science degree, Auditory Pathology and Speech Pathology. Prior to founding Bench, DeeDee served as a Research Fellow in a joint research program sponsored by National Institute of Health (NIH) and Siemens Corporation, the University of California, San Diego, State Diego State University and the San Diego Speech and Hearing Center.

Dwayne Nelson, J.D.

Dwayne is an attorney with a background in technology and intellectual property law. After a decade developing and protecting intellectual property at IBM, Dwayne moved to Southern California in 2013 to pursue a project of his own design. Today he remains active in the local start-up community by contributing as an expert-in-residence at schools and technology incubators.

Dwayne completed B.S. and M.S. degrees in Computer Science at Oakwood College and the University of Central Florida, his J.D. at Georgetown University Law Center. Dwayne is licensed to practice law in New York, New Jersey, the District of Columbia and in patent cases before the United States Patent and Trademark Office. Dwayne is a member of the National Association of Patent Practitioners.

Gail Christine Gannon

Gail Christine Gannon, Managing Director of Wave Edge Capital and Founder & CEO of Ensanté.

Gail advises entrepreneurs on how to turn their great idea into market success or translate their success into new markets while leaping regulatory hurdles. Her work in Europe, Asia, Africa and the Americas spans a wide range of products and services, from healthcare improvements to innovative technologies. In 2019, she traveled to advise DTC companies in Sardinia, U.S. angel investors in Bari (Italy), biotech firms in Tokyo, young entrepreneurs in Kuwait, and digital health innovators in Tbilisi (Georgia).

In the U.S., Gail mentors entrepreneurs in market and financing strategies throughout the Silicon Valley ecosystem, e.g. Stanford University’s SPARK and University of California-San Francisco’s Lean Launchpad. Gail routinely presents at major conferences on international biotechnology and digital health, and at investor forums (Health 2.0/HIMSS, BIO International, Keiretsu Forum/Wilson Family Office). Her past work includes helping governments and NGOs (e.g., Gates Foundation projects in India), allocate health dollars to the most promising innovations. Gail earned her master’s degree in public health at Harvard University and was a Patricia Roberts Harris Fellow.

Dr. Gina Zastrow-Hayes

Dr. Gina Zastrow-Hayes graduated with a degree in Microbiology from the University Wisconsin Madison in 2000 and since has worked in the field of Genomics spanning toxicology, cancer biology, circadian biology and agricultural research programs.

She established Genomics and cell-based screening facilities at the Scripps Research Florida campus and University of Pennsylvania and joined the Corteva Agriscience Genomics group in 2008 where she has helped expand the use of next generation sequencing technologies for breeding, transgene and gene editing applications.

Gina is currently a Technology Leader in the Genomics group and is responsible for a team that manages long and short read sequencing technologies including whole genome sequencing for reference genome production and targeted applications for the gene editing molecular characterization pipeline.

Kevin Hayes, Ph.D.

Experienced leader of a computational biology and software development team surrounding genomics data management and analysis. Expertise in leading teams and generating innovative solutions to large problems including, but not limited to Next Generation Sequencing. Prior experience in high throughput screening, data mining, experimental analysis, functional genomics, toxicogenomics and circadian rhythms.

As Global Lead, Data Science and Informatics Strategy and Communication at Corteva, Kevin is enabling definition and planning of strategies for initiatives that cross multiple domains within Data Science and Informatics. He is also collaborating with disparate teams within R&D and outside organizations, spearhead strategic planning across multiple data science/system disciplines and disseminate actionable plans to enable innovation while maximizing knowledge capture.
Additionally, Kevin leads the efforts surrounding external communication of Corteva Data Science and Informatics topics by working through multiple venues.

Jillian Sidoti, Esq.

Jillian is one of the country’s leading experts on securities Regulation A+. Since 2008, Jillian has submitted multiple Regulation A Offering Circulars to the Securities Exchange Commission for approval making her one of the few attorneys familiar with the law prior to the changes under the JOBS Act.

Since the JOBS Act, Jillian has assisted multiple companies and entrepreneurs realize their fundraising goals through Crowdfunding, 506©, and Regulation A. Jillian also continues to specialize in transactional legal matters such as private placement memorandums, S-1’s/S-11’s, and Regulation D filings.

Jillian also spends her time speaking at seminars educating real estate investors on how to legally raise capital for their real estate investment projects. Jillian is the author of the highly rated book, The Crowdfunding Myth which debunks the multiple myths surrounding crowdfunding and teaches the reader how to effectively crowdfund their securities offering.

Joe Cawley

Joe serves as a corporate development & investment banking advisor to entrepreneurs, Boards, C-Suites, & UHNW. He possesses significant in-country international operating and cross border transaction experience throughout APAC, EMEA and the Americas. He is currently advising clients on institutional grade, SEC compliant TGEs with a global team of over 100 blockchain / crypto / DLT / decentralization advisors, consultants, financiers, and legal experts in eighteen time zones.

Joe is relationship driven with start-up through IPO C-Suite operator experience and early stage tech venture capital Managing Director experience. This vast understanding of both buy and sell side transaction perspectives allows him to position, design, and execute at maximize client value. An expert in strategic planning/analysis, transaction execution/design, and financial modeling/valuation, he has generated and executed dozens of M&A, strategic partnership, and capital related transactions as an external independent advisor.

Specialties: Corporate Development, Growth Strategy, Alliances, Partnerships, M&A, Cross Border, SPV, Capital, Crypto, Divestment, Exits, International, Partnerships, Business Development, Technology, Biotechnology, Stem Cells, Genomics, Transgenics, Proteomics, MedTech, Healthcare, Blockchain, DLT, Digital, IT, Software, EdTech, Predictive Analytics, Big Data, Real Estate Development, Investments, Investment Banking, Capital, Venture Capital, Private Equity, Activist, UHNW, Sovereign, Seed, Series A, Series B, IPO, ICO, TGE, Tokens, Philanthropy, Social Impact, Non-Profit, Financial Models, Projections, DCF, Valuation, Business Plan Development & Evaluation, White Papers, Transaction Due-Diligence.

John Sninsky, Ph.D.

John is Chief Scientific Officer at CareDx, Inc., a California based molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients.

Dr. Sninsky is a member of American Association for the Advancement of Science, Association of Molecular Pathologists, American Society Human Genetics, American College Medical Genetics, American Association Cancer Research and American Association for the Study of Liver Disease. He is the author of more than 100 scientific papers including methods in molecular biology, application of the polymerase chain reaction (PCR) to virology and cancer, and genome-wide genetic association studies for multiple common, complex diseases.

Among John’s past awards are the Centers for Disease Control Charles C. Shepherd Science Award (1988), the Pan American Society for Clinical Virology Award (1992) and the Hoffmann-La Roche R & D Prize in 1997 for his efforts in applying PCR to virology and developing assays for measuring viral load in individuals with HIV. Dr. Sninsky was a recipient of the Purdue University Distinguished Alumni Award in 2001.

John brings experience in the discovery, development and application of diagnostic technologies, content and interpretive test solutions ranging from early stage biotechnology to international pharmaceutical organizations as well as in a range of small and enterprise diagnostic services and product settings.

Karen Landry

Karen Landry is a financial industry entrepreneur with more than 25 years of experience focused on business development, investment banking, sales, and marketing. Behind Karen’s success is her proven ability to create and maintain open and responsive relationships between investment managers and professional investors.

Karen is currently a Managing Director at Silver Leaf Partners, a provider of capital introduction services, and an Advisor to Benefunder, a marketplace for researchers and philanthropic donors.

Previously, Karen was a Managing Director of a Bay Area healthcare-focused investment banking firm, a partner of a San Francisco based hedge fund and raised capital for four Bay Area private equity funds.

Earlier in her career, Karen, co-founded Brad Peery Capital, an investment advisory firm that managed three limited partnerships in the media and telecommunications industry. As a Principal, Investment Banker and Syndicate Manager of an affiliated broker-dealer, Brad Peery Inc., Karen established the firm’s investment banking department and participated in over 250 underwritings. Karen is a member of 100 Woman in Hedge Funds and an alumna of the Woman’s Syndicate Association. She received her BS in Applied Economics from the University of San Francisco, is a California Registered Representative and holds FINRA license Series 7, 79 and 63.

Kristine Mayle, Ph.D.

Kristine leads Bench International’s corporate strategy, utilizing her skills in evaluating macro trends and competitive strategies in the life sciences industry. She plays a key role in the execution of Bench’s confidential and proprietary Board Diagnostic Assessments, identifying critical themes and recommendations for both public and private company Boards.

Prior to joining Bench, Kristine served as a Consultant at Deallus Strategic Intelligence Consulting, directing global teams in projects with Fortune 500- and Forbes Global 2000- ranked pharmaceutical and biotech companies.

Kristine holds a Ph.D. in Bioengineering from the University of California Los Angeles, which was supported in part by the prestigious National Science Foundation Graduate Research Fellowship, and a B.S. degree in Chemical Engineering from Ohio University.

Laura M. Robinson

Business Development, Sales and Marketing, Clinical Trials
Laura is a decisive leader with 25+ years of experience in the healthcare industry, with particular expertise in business development, sales/marketing strategy and clinical trials. She has demonstrated success in generating multimillion-dollar revenue by implementing innovative technology approaches in clinical trials market, establishing relationships with numerous pharmaceutical, biotechnology and medical device companies.

Laura is uniquely positioned to transition to the evolving healthcare information technology industry based on deep understanding of the healthcare market and integration of electronic medical records standards and software-based patient care solutions. She has a track record of utilizing strong analytical skills to evaluate marketplace and design strategy to secure new business, as shown by winning 6 Clinical Research Organization service contracts with cumulative value of $8.2M+.

Exceptional communicator with highly refined skills in negotiation and cultivating ongoing relationships, and significant global business experience through travel to 31 countries; speaks conversational French, beginning Mandarin.

Leila Colgan

Leila is an accomplished healthcare sales executive, business development leader and influencer. Her executive leadership experience in sales and marketing ranges from small start-up organizations to Fortune 500 companies within the pharmaceutical, biotechnology, and personalized medicine landscape.

Leila has spent her career implementing new sales and marketing initiatives to consistently drive revenue growth. These strategic initiatives have spanned multi-channel (regional, national, and global) to effectively position products and therapeutics to quickly secure solid market share.

Leila is a nationally recognized influencer among oncologists and key opinion leaders (KOLs), has led cross-functional teams, aggregated multiple advisory boards and commercialized sales teams to exceed revenue expectations. She is the recipient of multiple local and national achievement awards.

Leila has extensive business development experience in biotechnology, molecular diagnostics, pharmaceuticals, genomics, next-generation sequencing, biomarkers, innovation, and personalized medicine. Her deep knowledge ranges across therapeutic, diagnostic and the liquid biopsy landscape; inclusive of oncology, cardiology, neurology, gastroenterology, psychiatry, nephrology, infectious disease, pulmonology, endocrinology, rheumatology, HIV, womenís health and wellness.

Leila received both her Bachelorís of Arts (B.A.) and Executive MBA (EMBA) from Pepperdine University, CA, graduating with Beta Gamma Sigma Honors. She is an active member of the Healthcare Businesswomen’s Association (HBA), Women in Bio, a Council Member of the American Cancer Society, member Kappa Kappa Gamma Sorority, a chosen Ambassador of Pepperdine University, and an active member of her Alumni association.

Marek Ciszewski, J.D.

Marek has 25 years of Wall Street experience as a portfolio manager and equity analyst with leading financial institutions. Most recently, he worked at BMO Global Asset Management, one of the world’s largest asset managers, as the global head of healthcare research. His other experience includes Vestor Capital, Nesbitt Burns Securities and Perritt Capital Management.

Throughout his investment career, Ciszewski acquired extensive experience in fundamental security analysis and selection, portfolio management and investment strategy. This was underpinned by his innate curiosity and relentless focus on understanding the various business models in the life sciences industry.

Ciszewski’s understanding of investor relations and capital markets is further complemented by his biopharma industry experience. He has held various senior corporate roles, including vice president of corporate development at Verastem, an oncology-focused biopharmaceutical firm, and head of investor relations and corporate communications at Epirus Biopharmaceuticals, a biosimilars pioneer.

His passion for his craft and unique combination of skills, experience and education make him invaluable to companies both preparing to go public and existing public companies that require deep industry knowledge along with a comprehensive suite of IR services.

Mark Mitchell

Mark is the Executive Director of Corporate and Business Innovation for the Riverside Community College District. He is the former Executive Director of TriTech SBDC, an SBA organization that worked with high technology high growth firms by offering no cost consulting and training to entrepreneurs and businesses looking for go-to-market strategies that will accelerate the growth of their enterprise. Mark led TriTech SBDC to be the fifth highest producing SBDC in terms of Economic Impact in the nation and the highest performing organization out of 950 SBDCs in ROI.

As a public speaker, Mark has delivered programs on leadership, sales, marketing, customer service and team building that resulted in a workforce that was inspired with new tools to unleash their personal power to achieve higher levels of excellence. He has received the U.S. Small Business Administration Small Business Development Center Service Excellence and Innovation Center Award and the California Small Business Development Center Service Excellence & Innovation Award.

Michael Shimokaji, Esq.

Michael’s expertise includes the strategic development of patent and trademark portfolios. He identifies those patents and trademarks that are valuable to his clients by providing them with a competitive advantage. Then, Michael obtains patent and trademark registrations in the US and abroad.

He also works on business transactions – sales, mergers, and licenses – where intellectual property is involved. Michael assists a party to the transaction in evaluating the worth of patents, trademarks and copyrights being bought, sold or licensed.

He specializes in the health care industry, including medical devices, medtech, and life sciences. Over the last 30 years, Michael has also supported clients in industries as diverse as aerospace, apparel, chemicals, computer hardware/software, consumer household products, photocopiers, restaurants, semiconductors, and telecommunications.

Nicholas J. Schork, Ph.D.

Dr. Schork is Director of Bioinformatics and Biostatistics at the Scripps Translational Science Institute; Director of Research, Scripps Genomic Medicine; and Professor, Department of Molecular and Experimental Medicine at The Scripps Research Institute.

Dr. Schork’s interest and expertise is in the areas of quantitative human genetics and genomics, especially the design and implementation of methodologies used to dissect the genetic basis of complex traits and diseases. Dr. Schork was a Professor of Biostatistics and Psychiatry, and Co-Director of the Center for Human Genetics and Genomics at the University of California, San Diego as well as an Associate Professor of Epidemiology and Biostatistics at Case Western Reserve University in Cleveland, Ohio and an Associate Professor of Biostatistics at Harvard University.

Between 1999 and 2000 Dr. Schork took a leave of absence to conduct research as the Vice President of Statistical Genomics at the French Biotechnology company, Genset, where he helped guide efforts to construct the first high-density map of the human genome.

Dr. Schork has been selected as a member of several scientific journal editorial boards, is a frequent participant in U.S. National Institutes of Health-related steering committees and review boards and has also been on the advisory board of six companies.

He is currently Director of the Bioinformatics and Biostatistics Core of the NIA-sponsored Longevity Consortium and a member of the NHGRI’s Genetic Association Information Network (GAIN) data analysis committee.

Dr. Schork has published over 400 scientific articles and book chapters on the analysis of complex, multifactorial traits and diseases. Dr. Schork earned a B.A. in Philosophy, an M.A. in Philosophy, an M.A. in Statistics, and a Ph.D. in Epidemiology all from the University of Michigan in Ann Arbor, Michigan.

Paul Wendee, Ph.D.

Paul is the editor and publisher of the Intrinsic Value Wealth Report Newsletter (, an investment newsletter; and the Intrinsic Value Wealth Report (, an educational and research website. He is also the Managing Director of Paul M. Wendee & Associates, LLC, a corporate finance, private equity, and management consulting firm. The firm is an investment adviser registered with the State of California.  In addition to corporate finance and management consulting, the firm’s consulting activities have included fundamental equity analysis and research, quantitative research, convertible securities research and analysis, technical research, investment management, due diligence and valuation services to securities broker/dealers, hedge funds, money managers and investment banking firms. Paul was the President and majority owner of South Lake Avenue Securities Corporation, a boutique investment banking, management consulting, mergers & acquisitions (M&A), business appraisal, investment management firm and FINRA registered broker-dealer headquartered in Pasadena, California. Paul was the founding project manager and the Vice President of Administration of Evergreen Realty REIT, Inc. Paul was Director of Equity Research for Skye Investment Advisors, LLC, where he was responsible for fundamental equity analysis, research and valuation.  Paul was the Director of Research and the Director of Corporate Finance at Brookstreet Securities Corporation.  In this capacity, he had overall responsibility for corporate finance; equity research; due diligence; direct participation programs (real estate, oil & gas, equipment leasing, etc.); and Investment Advisory product analysis, selection and development.  Paul also co-managed the Corporate Finance Department and was Director of Due Diligence for First Affiliated Securities. Paul was a portfolio manager with Harris Trust Bank of Arizona, a wholly‑owned subsidiary of Harris Bankcorp in Chicago, where he managed in excess of $200 million in personal trust and employee benefit (profit sharing and pension) investments.

Paul earned his Bachelor of Science degree in Economics and Administrative Studies (Graduation with Honors and Distinguished Military Graduate) and his Master of Administration in Business degree with emphases in Finance and Marketing from the University of California, Riverside.  He was awarded an Army R.O.T.C. Scholarship and served as an officer in the United States Army.  Paul earned his Doctor of Business Administration (DBA) degree from the University of Phoenix. He created a new theory in finance and wrote his doctoral dissertation entitled, A Theory of Value Drivers: A Grounded Theory Study, on the new theory. He is a Certified Financial PlannerTM Professional, a Certified Business Intermediary and holds the following securities registrations:  General Securities Representative (Series 7), General Securities Principal (Series 24), Investment Banking Representative (Series 79), and Registered Investment Advisor (Series 65).  Paul also holds an inactive Arizona Real Estate Salesperson License.

Paul founded the Value Driver Institute and Research and Educational Expedition Programs (VDI/REEP), a non-profit organization with a mission to conduct research on enterprise value driver theory and the enterprise value creation process; and to take the business incubator concept to places in the world where business incubators are not commonly found, but where they are needed the most. The Value Driver Institute and Paul have introduced the business incubator concept to many groups and individuals on a world-wide basis. A previous VDI/REEP expedition organized and accompanied famed astronomer John Dobson on an astronomy expedition to Death Valley, CA.
Paul is a Member the National Association for Business Economics (NABE) and the International Business Brokers Association, Inc. (IBBA); and is a past member of the Direct Investment and Membership Committees of the Securities Industry Association (SIA).  He has written investment related articles for the Tucson Citizen and been quoted in numerous publications including The Wall Street Journal, USA Today, The San Diego Union‑Tribune, The Wall Street Transcript, Buyside Magazine, and Wall Street Research Magazine.  His article on Economic forecasting, “A Simple and Effective Economic Forecasting Model,” was published in Strategic Investor Relations (a publication of Institutional Investor).  He wrote an article on financing equestrian enterprises for California Riding Magazine entitled: “Grassroots enterprise financing is one of several funding sources for equestrian endeavors.”  He is a winner of The Wall Street Journal’s Experts Vs. Darts stock picking contest.  Paul was previously the Department Chair of the College of Arts & Sciences and the Graduate School of Business and Management at Argosy University’s Orange County Campus. Paul has taught courses in finance, including courses in security analysis and portfolio management, as a member of the Adjunct Faculty at National University and other universities. Paul also teaches finance and management courses at DeVry University’s Keller Graduate School of Management.  He is an Adjunct Faculty Professor, an Entrepreneur-In-Residence and Senior Mentor advising entrepreneurial students at Chapman University. He is an Entrepreneur-In-Residence at the University of California, Irvine and a Lecturer at Cal State LA. Paul also is an Adjunct Professor at California Baptist University, where he teaches finance, economics, and investments. He was a volunteer instructor at Los Angeles-based Chrysalis, a non-profit organization dedicated to creating a pathway to self-sufficiency for homeless and low-income individuals. Paul is a Research Fellow at the Center for Global Business and Information Technology Research at the University of Phoenix. He is a frequent speaker at various workshops, symposiums and conferences speaking on a variety of topics.

Ronnie Andrews

Ronnie Andrews is the Founder and Principal of The Bethesda Group, a company focused on helping organizations in the molecular diagnostics and genomics industries. Prior to founding The Bethesda Group, he served as President of the Genetic Sciences Division at Thermo Fisher Scientific following a merger with Life Technologies, where he served as President of the Medical Sciences Venture. During the merger, he oversaw the integration of Ion Torrent with the traditional genetic platform and content initiatives within Life Technologies to form a $2 billion division.

Previously, Ronnie served as Chief Executive Officer and Segment Leader of GE Molecular Diagnostics at Clarient Inc. from 2004 until 2012. During this time, he oversaw the transition into GE Healthcare and established a strategic plan to integrate In Vivo and In Vitro and expand GE’s presence in oncology. While at Clarient, he transformed ChromaVision Medical Systems from a device manufacturer to a comprehensive cancer diagnostics company.

Ronnie currently serves on the Board of Directors of Insight Genetics, Orion Healthcare, and Oxford Immunotec.

Scott Brovsky

Scott is an angel investor, startup mentor and the Director of EPIC SBDC at the University of California Riverside.

Scott has been a Founder or Founding Executive of a number of startups including the VC funded mobile games studio Muti Labs, the Temecula based sports tech company NZN Labs/LIT Pro and he sold his first company, Industrial Strength Network (an early interactive agency), to frog design as an acquihire in 1998.

Scott was part of the global leadership team at Disney that worked for the three years to build The Avengers franchise into a global powerhouse with his focus being the interactive games space. He led the successful launch of Avengers Alliance on Facebook and Avengers Initiative on mobile and with 40 million plus people having played the games, they have been a hit with the fans and critics alike.

Scott pioneered a big idea and an industry first, premiering The Hulk TV spot promoting the film in the Facebook game before it aired on national television. He championed and helped build a community called Marvel XP – a free live service that tracks gamer progression, rewards achievement and provides connected storytelling across Marvel mobile and social games. Scott has a Humanities Honors degree from The University of Texas at Austin where he graduated Magna Cum Laude and Phi Beta Kappa.

Shepard Bentley, RAC

Shep began his career in 1984 at the Hospital Corporation of America as a research technician, produced drugs at Kendall-McGaw Laboratories, Inc. in Irvine, and became responsible for GMP compliance.

He has since become a regulatory affairs consultant, joining the Drug Information Association, speaking at the Parenteral Drug Association and joining the managements of ACTUS Biotech, Pharmakos, Inc., the Board of Directors of the Life Sciences Industry Council (LINC) of Orange County/Los Angeles County, and the Program Committee of the Orange County Regulatory Affairs Discussion Group.

He has been responsible for regulatory strategies leading to FDA and foreign approvals for several biotech companies. He has achieved market entry for numerous innovative medical technologies and applications within the European Union, Canada, Brazil and across Asia. Previously, Shep formed Synergy Biomedical, LLC, served as its President in collaboration with Washington D.C.-based Synergy, Inc. to provide biomedical regulatory expertise to the device and pharmaceutical industry of Southern California.

He speaks regularly at regulatory conferences, has co-authored a book on regulatory strategy as well as contributed to Genetic Engineering & Biotech News (GEN), and provides independent consulting for clients of Intertek.

He is an active member of the American Society for Quality – Biomedical Section (ASQ), the Regulatory Affairs Professional Society (RAPS), and The Organization for Professional Regulatory Affairs (TOPRA).

Mr. Bentley also served eight years of active duty as an officer in the United States Marine Corp, including as a part of the Marine Expeditionary Force (Forward), deployed to Ash Shuaybah, Kuwait, to prosecute the invasion into Baghdad, Iraq, and then redeployed to Office of Force Transformation, in the Pentagon. He was awarded the Meritorious Service Medal by the President of the United States, twice, and retired from military service in 2005.

Stephen G. Austin, CPA, MBA

Steve Austin, MBA, CPA is Managing Partner for Swenson Advisors, LLP, a regional CPA firm (registered with the PCAOB), specializing in audit, tax, SEC, Sarbanes-Oxley, lease accounting and consulting engagements with a focus on technology, manufacturing, service, software, real estate, and non-profit organizations.

Steve manages audit, SEC, Sarbanes-Oxley, and business consulting engagements with a focus on technology, manufacturing, service, real estate, social media, and non-profit organizations. He is the author of the book “Rise of the New Ethics Class.” Steve speaks worldwide on governance, Sarbanes-Oxley, and IFRS matters and writes articles published by the AICPA.

Prior to joining Swenson Advisors, LLP, Mr. Austin accumulated over 22 years of experience as an Audit Partner with Price Waterhouse LLP, where he worked from 1976 to 1996, and with McGladrey & Pullen, LLP, where he worked from 1996 to 1998, serving both public and private companies. While at Price Waterhouse, Mr. Austin worked in the PW National Office in New York, where he addressed complex accounting and reporting issues for publicly-traded companies and worked with various members of the FASB and EITF staffs.

Strategic Relationships

We have established a number of partnerships with like-minded organizations from around the world. Here is a list of some of the organizations that we are working with:

Murrieta Genomics is a member of Genomics England’s Discovery Forum.

It is estimated that one in seventeen people are born with or develop a rare disease during their lifetime. At least 80% of rare diseases have an identified genetic component, with 50% of new cases of rare diseases being identified in children. However, it can take considerable time and expense between a patient first presenting at a doctors and receiving an accurate diagnosis. The time taken to sequence a whole human genome has been dramatically reduced and will become more affordable for routine use as the price continues to fall.

Genomics England is a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to sequence 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. Genomics is made up of many moving parts − from the understanding and consent of the public, to truly pioneering research, to building an effective NHS infrastructure. The Discovery Forum and the industry partnerships it builds are every bit as important to the success of genomic medicine.

Murrieta Genomics is a member of the Global Alliance for Genomics and Health.

The Global Alliance for Genomics and Health (GA4GH) is an international, nonprofit alliance formed in 2013 to accelerate the potential of research and medicine to advance human health. Bringing together 500+ leading organizations working in healthcare, research, patient advocacy, life science, and information technology, the GA4GH community is working together to create frameworks and standards to enable the responsible, voluntary, and secure sharing of genomic and health-related data. All of our work builds upon the Framework for Responsible Sharing of Genomic and Health-Related Data.

GA4GH Connect is a five-year strategic plan that aims to drive uptake of standards and frameworks for genomic data sharing within the research and healthcare communities in order to enable responsible sharing of clinical-grade genomic data by 2022. GA4GH Connect links our Work Streams with Driver Projects—real-world genomic data initiatives that help guide our development efforts and pilot our tools.

Murrieta Genomics is a member of SoCalBio.

Southern California Biomedical Council (SoCalBio) is a nonprofit, member-supported trade association that serves the biotech, med tech, IVD and digital health communities in the six counties that comprise the Greater Los Angeles region (Los Angeles, Orange, Ventura, Santa Barbara, Riverside and San Bernardino). SoCalBio’s programs help local firms gain access to capital, potential partners, and other business services. The Council also promotes technology transfer and workforce training, while informing policymakers and the public at-large about the benefits of the region’s bioscience industry. SoCalBio is open to membership by firms and organizations engaged in all aspects of bioscience research, technology development, and commercialization. All of the incubator companies at Murrieta Genomics receive a complimentary membership to SoCalBio.

Murrieta Genomics is a member of Biocom.

Founded in 1995 in San Diego, Biocom provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Biocom operates core offices in San Diego, Los Angeles and the San Francisco Bay Area, satellite offices in Washington, D.C. and Tokyo, and has a continuous staff presence in Sacramento. Biocom works on behalf of over 1,300 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge workforce development and STEM education programs, and create robust value-driven purchasing programs. Biocom provides the strongest public voice for research institutions and life science companies that fuel the California economy.

Subscribe to our Newsletter

Join our newsletter